CO2018006667A2 - Moléculas de anticuerpo multiespecífico que tienen especificidad para tnf-alfa, il-17a e il-17f - Google Patents

Moléculas de anticuerpo multiespecífico que tienen especificidad para tnf-alfa, il-17a e il-17f

Info

Publication number
CO2018006667A2
CO2018006667A2 CONC2018/0006667A CO2018006667A CO2018006667A2 CO 2018006667 A2 CO2018006667 A2 CO 2018006667A2 CO 2018006667 A CO2018006667 A CO 2018006667A CO 2018006667 A2 CO2018006667 A2 CO 2018006667A2
Authority
CO
Colombia
Prior art keywords
antibody molecules
tnf
specificity
alpha
multispecific antibody
Prior art date
Application number
CONC2018/0006667A
Other languages
English (en)
Inventor
David Paul Humphreys
Stevan Graham Shaw
Diane Marshall
Pallavi Bhatta
Emma Dave
Sam Philip Heywood
Ralph Adams
Daniel John Lightwood
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CO2018006667A2 publication Critical patent/CO2018006667A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

RESUMEN La invención se refiere a moléculas de anticuerpo multiespecífico que tienen especificidad para TNF-alfa, IL-17A e IL-17F, a usos terapéuticos de las moléculas de anticuerpo y a métodos para producir dichas moléculas de anticuerpo.
CONC2018/0006667A 2015-12-18 2018-06-27 Moléculas de anticuerpo multiespecífico que tienen especificidad para tnf-alfa, il-17a e il-17f CO2018006667A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522391.0A GB201522391D0 (en) 2015-12-18 2015-12-18 Antibody molecules
PCT/EP2016/080979 WO2017102830A1 (en) 2015-12-18 2016-12-14 Multi-specific antibody molecules having specificity for tnf-alpha, il-17a and il-17f

Publications (1)

Publication Number Publication Date
CO2018006667A2 true CO2018006667A2 (es) 2018-07-10

Family

ID=55311227

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0006667A CO2018006667A2 (es) 2015-12-18 2018-06-27 Moléculas de anticuerpo multiespecífico que tienen especificidad para tnf-alfa, il-17a e il-17f

Country Status (25)

Country Link
US (1) US20200277366A1 (es)
EP (1) EP3390445A1 (es)
JP (1) JP2019502380A (es)
KR (1) KR20180089514A (es)
CN (1) CN108473568A (es)
AR (1) AR107735A1 (es)
AU (1) AU2016369307A1 (es)
BR (1) BR112018011860A2 (es)
CA (1) CA3007493A1 (es)
CL (1) CL2018001660A1 (es)
CO (1) CO2018006667A2 (es)
EA (1) EA201891446A1 (es)
EC (1) ECSP18054047A (es)
GB (1) GB201522391D0 (es)
IL (1) IL259645A (es)
MA (2) MA44061A (es)
MX (1) MX2018007289A (es)
PH (1) PH12018501141A1 (es)
RU (1) RU2018126318A (es)
SG (1) SG11201804803WA (es)
TN (1) TN2018000200A1 (es)
TW (1) TW201726731A (es)
UY (1) UY37035A (es)
WO (1) WO2017102830A1 (es)
ZA (1) ZA201803681B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005031A (es) 2015-10-27 2018-06-13 Ucb Biopharma Sprl Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f).
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
CN110551215A (zh) * 2018-05-30 2019-12-10 中山康方生物医药有限公司 抗白细胞介素-17a抗体、其药物组合物及其用途
SG11202107995SA (en) 2019-01-31 2021-08-30 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2022223152A1 (en) * 2021-02-19 2023-08-31 Innovent Biologics (Suzhou) Co., Ltd. Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
CN117642423A (zh) * 2021-09-13 2024-03-01 深圳华普药物研发有限公司 一种il17抗体及其制备方法和应用
CN114380917B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 针对IL-17A和TNFα的双特异性单域抗体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790163B2 (en) * 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
KR20170023209A (ko) * 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
UA117218C2 (uk) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
UY34410A (es) * 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
WO2015014979A1 (en) * 2013-08-01 2015-02-05 F. Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies

Also Published As

Publication number Publication date
MX2018007289A (es) 2018-09-28
MA42743A1 (fr) 2019-07-31
CN108473568A (zh) 2018-08-31
KR20180089514A (ko) 2018-08-08
EP3390445A1 (en) 2018-10-24
WO2017102830A1 (en) 2017-06-22
RU2018126318A (ru) 2020-01-20
ZA201803681B (en) 2019-09-25
AR107735A1 (es) 2018-05-30
ECSP18054047A (es) 2018-07-31
AU2016369307A1 (en) 2018-07-12
UY37035A (es) 2017-07-31
TW201726731A (zh) 2017-08-01
CA3007493A1 (en) 2017-06-22
TN2018000200A1 (en) 2019-10-04
MA44061A (fr) 2018-10-24
CL2018001660A1 (es) 2018-10-19
BR112018011860A2 (pt) 2018-12-04
IL259645A (en) 2018-07-31
RU2018126318A3 (es) 2020-05-20
JP2019502380A (ja) 2019-01-31
SG11201804803WA (en) 2018-07-30
EA201891446A1 (ru) 2018-11-30
GB201522391D0 (en) 2016-02-03
PH12018501141A1 (en) 2019-01-28
US20200277366A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
CO2018006667A2 (es) Moléculas de anticuerpo multiespecífico que tienen especificidad para tnf-alfa, il-17a e il-17f
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CO6781516A2 (es) Moléculas de anticuerpos que se unen a il-17a y il-17f
CR20160347A (es) Moléculas de anticuerpo que se unen a tim-3 y usos de las mismas
CR20170540A (es) Formas de dosificación solidas de palbociclib
DK3283511T3 (da) Modified collagen, methods of manufacture thereof
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
UY37018A (es) Inhibidores bicíclicos de pad4
DK3381469T3 (da) Anti-erbb2 antistoflægemiddelskonjugat og sammensætning deraf, fremgangsmåde til fremstilling deraf og anvendelse deraf
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
BR112017024676A2 (pt) ?métodos para produzir biohidrocarbonetos e mistura de biohidrocarbonetos?
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CY1120718T1 (el) Αντι-αναρροϊκη συνθεση που διατηρει την κινητικοτητα του εντερου
BR112017009289A2 (pt) métodos de administrar composições de amantadina
ES2874374T8 (es) Proceso para producir hidrógeno
CL2018001135A1 (es) Métodos de tratamiento usando anticuerpos anti - il 17a/17f (il-17a/f)
EA201791423A1 (ru) Способ получения белка
EA201792578A1 (ru) Многослойная сборка
CL2018001661A1 (es) Moléculas de anticuerpo que se unen a tnf alfa
EA201991474A1 (ru) Способы получения фитоина
DK3393639T3 (da) Porøs membran og fremgangsmåde til fremstilling deraf
FR3044676B1 (fr) Dendrimeres photosensibilisateurs biphotoniques, procede de fabrication et utilisations
DK3261632T3 (da) Kosttilskud til forbedring af fysiologiske reaktioner relateret til posttraumatisk stresslidelse
TH1501004021B (th) วิธีการดึงขึ้นรูปด้วยการกด